Juno Therapeutics, Inc. (NASDAQ:JUNO) Posts Basic Consolidated EPS Of $-2.7157

0

Juno Therapeutics, Inc. (NASDAQ:JUNO)managed to report annual basic consolidated EPS of $-2.7157, which was for the year ended2015-12-31.The company reported basic consolidated EPS of $-2.7157 for the quarter ended 2015-12-31.

EPS from continuing operations

If you look at the performance of the company’s continuing operations, you see that EPS generated from such operations was {EPS_BASIC_CONT_OPER:1541}} for the year ended 2015-12-31. As for the quarter ended 2015-12-31, continuing operations produced EPS of $-0.6388.

EPS contribution from parent

Juno Therapeutics, Inc. (NASDAQ:JUNO) received of $-2.7157 EPS boost from the parent company for the annual period ended

For the year ended 2015-12-31, the parent of Juno Therapeutics, Inc. (NASDAQ:JUNO) contributed EPS of $-2.7157 to the company’s bottom-line. But for the quarter ended 2015-12-31, EPS boost from the parent was cited as $-2.7157.

What About Basic net EPS

The basic net EPS that Juno Therapeutics, Inc. (NASDAQ:JUNO) reported for the year ended 2015-12-31 stood at $-2.72. For the quarter ended 2015-12-31, the company posted basic net EPS of $-2.72.

What About Consolidated Diluted EPS?

Juno Therapeutics, Inc. (NASDAQ:JUNO)’s consolidated diluted EPS for the year ended 2015-12-31 was reported as $-2.7157. For the quarter ended 2015-12-31 the metric was$-2.7157.

Basic diluted EPS

The company managed to register diluted EPS from continuing operation of at $-2.7157 for the yearended 2015-12-31. But diluted EPS from continuing operations for the quarter ended 2015-12-31 came in at $-2.7157.

Net diluted EPS

Net diluted EPS posted by Juno Therapeutics, Inc. (NASDAQ:JUNO) for the year ended 2015-12-31 was $-2.72. On quarterly basis, net diluted EPS for the quarter ended 2015-12-31 was reported as $-2.72.

What portion of diluted EPS came from parent?

For the annual period ended 2015-12-31, the parent company of Juno Therapeutics, Inc. (NASDAQ:JUNO) said that it parent company boosted its diluted EPS by$-2.7157 in the year ended 2015-12-31. For the quarter ended 2015-12-31, the parent company’s contribution to diluted EPS was $-2.7157.

The company reported net basic EPS of $-2.72 for the year ended 2015-12-31 and net basic EPS of $-2.72 for the quarter ended 2015-12-31.

The number of Juno Therapeutics, Inc. (NASDAQ:JUNO)’s basic shares outstanding at the end of the annual period ended 2015-12-31 was 88.145. That compares with 88.145 basic shares outstanding for the quarter ended 2015-12-31.

Juno Therapeutics, Inc. (NASDAQ:JUNO) had 88.145 diluted shares outstanding at the end of the annual period ended 2015-12-31. But for the quarter ended 2015-12-31, diluted outstanding shares were 88.145.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 34 times, 1 visits today)